The Role of Magnetic Resonance Imaging and Endoscopic Ultrasound Imaging in the Diagnosis and Management of Pancreatic Neuroendocrine Tumors (pNET) in Patients with Multiple Endocrine Neoplasia Type 1 (MEN1) Abstract #2285

Introduction: Pancreatic neuroendocrine tumors (pNETs) in patients with Multiple Endocrine Neoplasia Syndrome type 1 (MEN 1) are frequently multiple and occur with an incidence that varies from 30-80% in different series. Magnetic Resonance Imaging (MRI) and techniques such as endoscopic ultrasound (EUS) are useful tools for tumor localization, size assessment and follow-up.
Aim(s): The aim of the study was to compare imaging with MRI and EUS in pNET assesment in patients with MEN1.
Materials and methods: We collected retrospectively the data of 47 patients (mean age (±SD) at diagnosis 39±14 years, median: 39 years) with MEN1; 32 patients had pNETs. We analyzed and compared MRI and EUS findings ordered in the same follow-up visit and performed within the same trimester. We have analyzed the number and size of pancreatic lesions.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Marina Tsoli

To read results and conclusion, please login ...

Further abstracts you may be interested in

#81 Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): our experience in a multidisciplinary team in a university hospital
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have a low incidence and prevalence representing < 2% of all gastrointestinal tumors with a heterogeneous biological behavior and an often complex management.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Jose Manuel Cabezas-Agricola
#83 Surgical treatment of duodenopancreatic neuroendocrine tumors (pNETs) in patients with multiple endocrine neoplasia type 1 (MEN 1): a Dutch consensus statement
Introduction: Duodenopancreatic neuroendocrine tumors (pNETs) in multiple endocrine neoplasia type 1 (MEN 1) are the most important cause of MEN 1-related death. Surgery is the only curative treatment, but controversy exists on the optimal strategy. Recent guidelines on pNETs have limited recommendations specific for MEN 1. Therefore, a Dutch multidisciplinary consensus meeting was organized.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Carolina RC Pieterman
#199 Magnetic Resonance Imaging (MRI) v. Endoscopic Ultrasonography (EUS) for the Detection of =10-mm Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1 (MEN1). A GTE Study
Introduction: In MEN1, the main risk factor of metastases is pancreatic tumor size. We and others recommend limiting surgery to pancreatic tumors >20 mm or growing based on their size measured with EUS.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Guillaume Cadiot
#666 Ability of Tumor Markers for Predicting Future Metastatic Disease in MEN-1 Patients with a Pancreatic Neuroendocrine Tumor
Introduction: The diagnostic value of tumor markers in the follow-up of MEN-1 patients with a pancreatic neuroendocrine tumor (pNET) is unclear.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: MD Joanne De Laat
Keywords: MEN-1, tumor marker, pNET, SSA
#901 Impact of Long-Acting Octreotide in Patients with Early-Stage MEN1-Related Duodeno-Pancreatic Neuroendocrine Tumors
Introduction: Somatostatin analogues (SSA) represent one of the main therapeutic options in patients affected by functioning well-differentiated neuroendocrine tumors (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1).
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Valeria Ramundo